< Back to Article

Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis

Fig 3

Estimated disaggregated discounted cumulative costs for the simulated period 2017 to 2036.

Negative costs represent savings. The shaded areas depict 95% uncertainty intervals. USD, US dollars.

Fig 3